TWI754345B - Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat - Google Patents

Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat Download PDF

Info

Publication number
TWI754345B
TWI754345B TW109126981A TW109126981A TWI754345B TW I754345 B TWI754345 B TW I754345B TW 109126981 A TW109126981 A TW 109126981A TW 109126981 A TW109126981 A TW 109126981A TW I754345 B TWI754345 B TW I754345B
Authority
TW
Taiwan
Prior art keywords
mangosteen
acid bacteria
fermentation
acetic acid
liquid
Prior art date
Application number
TW109126981A
Other languages
Chinese (zh)
Other versions
TW202108160A (en
Inventor
林詠翔
莊偉秀
Original Assignee
大江生醫股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大江生醫股份有限公司 filed Critical 大江生醫股份有限公司
Publication of TW202108160A publication Critical patent/TW202108160A/en
Application granted granted Critical
Publication of TWI754345B publication Critical patent/TWI754345B/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A use of Garcinia mangostana fermented liquid is for preparing a composition. The composition has one or more of the following functions: enhancing antioxidant activity, inhibiting the formation of advanced glycation end products (AGEs), inhibiting the formation of tyrosinase, inhibiting fat accumulation, reducing the body fat of a recipient, and improving skin condition. And, the Garcinia mangostana fermented liquid is obtained by performing a fermentation process on a Garcinia mangostana culture medium and a plurality of strains.

Description

山竹發酵液用於製備美肌及/或減脂組合物的用途Use of mangosteen fermentation broth for preparing skin-beautifying and/or fat-reducing compositions

本發明是關於山竹相關產品，特別是關於山竹發酵液用於製備美肌及/或減脂組合物的用途。The present invention relates to mangosteen-related products, in particular to the use of mangosteen fermentation broth for preparing skin-beautifying and/or fat-reducing compositions.

自有機及天然的飲食概念興起後，生技公司及食品業者積極投入關於天然植物的相關產品之研發。為使植物相關產品對身體健康助益有科學驗證的基礎，植物的活性成分分析及功效評估成為產品開發的重點項目。而原產於東南亞地區的山竹（Garcinia mangostana）亦成為研究開發的對象之一。Since the rise of the concept of organic and natural diets, biotechnology companies and food companies have been actively investing in the research and development of natural plant-related products. In order to make plant-related products have a scientifically proven basis for their health benefits, active ingredient analysis and efficacy evaluation of plants have become key items in product development. The mangosteen (Garcinia mangostana) native to Southeast Asia has also become one of the objects of research and development.

在一實施例中，一種山竹發酵液的用途，其是用於製備用以提升抗氧化活性的組合物。其中，山竹發酵液是由一山竹培養液與及複數菌種進行一發酵程序所得。山竹培養液包括山竹及水，且山竹與水的比例為1:2-5。相對於山竹培養液，複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In one embodiment, the use of a mangosteen fermentation broth is for preparing a composition for enhancing antioxidant activity. Wherein, the mangosteen fermentation liquid is obtained by performing a fermentation procedure with a mangosteen culture liquid and a plurality of bacterial species. The mangosteen culture solution includes mangosteen and water, and the ratio of mangosteen to water is 1:2-5. Compared with the mangosteen culture medium, the multiple strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria.

在一實施例中，一種山竹發酵液的用途，其是用於製備用以抑制糖化終產物形成的組合物。其中，山竹發酵液是由一山竹培養液與及複數菌種進行一發酵程序所得。山竹培養液包括山竹及水，且山竹與水的比例為1:2-5。相對於山竹培養液，複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In one embodiment, the use of a mangosteen fermentation broth is for preparing a composition for inhibiting the formation of end products of saccharification. Wherein, the mangosteen fermentation liquid is obtained by performing a fermentation procedure with a mangosteen culture liquid and a plurality of bacterial species. The mangosteen culture solution includes mangosteen and water, and the ratio of mangosteen to water is 1:2-5. Compared with the mangosteen culture medium, the multiple strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria.

在一實施例中，一種山竹發酵液的用途，其是用於製備用以抑制酪胺酸酶形成的組合物。其中，山竹發酵液是由一山竹培養液與及複數菌種進行一發酵程序所得。山竹培養液包括山竹及水，且山竹與水的比例為1:2-5。相對於山竹培養液，複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In one embodiment, the use of a mangosteen fermentation broth is for preparing a composition for inhibiting the formation of tyrosinase. Wherein, the mangosteen fermentation liquid is obtained by performing a fermentation procedure with a mangosteen culture liquid and a plurality of bacterial species. The mangosteen culture solution includes mangosteen and water, and the ratio of mangosteen to water is 1:2-5. Compared with the mangosteen culture medium, the multiple strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria.

在一實施例中，一種山竹發酵液的用途，其是用於製備用以抑制脂肪累積的組合物。其中，山竹發酵液是由一山竹培養液與及複數菌種進行一發酵程序所得。山竹培養液包括山竹及水，且山竹與水的比例為1:2-5。相對於山竹培養液，複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In one embodiment, the use of a mangosteen fermentation broth is for preparing a composition for inhibiting fat accumulation. Wherein, the mangosteen fermentation liquid is obtained by performing a fermentation procedure with a mangosteen culture liquid and a plurality of bacterial species. The mangosteen culture solution includes mangosteen and water, and the ratio of mangosteen to water is 1:2-5. Compared with the mangosteen culture medium, the multiple strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria.

在一實施例中，一種山竹發酵液的用途，其是用於製備用以減少一受體的體脂肪的組合物。其中，山竹發酵液是由一山竹培養液與及複數菌種進行一發酵程序所得。山竹培養液包括山竹及水，且山竹與水的比例為1:2-5。相對於山竹培養液，複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In one embodiment, the use of a mangosteen fermentation broth is for the preparation of a composition for reducing body fat in a recipient. Wherein, the mangosteen fermentation liquid is obtained by performing a fermentation procedure with a mangosteen culture liquid and a plurality of bacterial species. The mangosteen culture solution includes mangosteen and water, and the ratio of mangosteen to water is 1:2-5. Compared with the mangosteen culture medium, the multiple strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria.

在一實施例中，一種山竹發酵液的用途，其是用於製備用以改善肌膚狀況的組合物。其中，山竹發酵液是由一山竹培養液與及複數菌種進行一發酵程序所得。山竹培養液包括山竹及水，且山竹與水的比例為1:2-5。相對於山竹培養液，複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In one embodiment, the use of a mangosteen fermentation broth is for preparing a composition for improving skin condition. Wherein, the mangosteen fermentation liquid is obtained by performing a fermentation procedure with a mangosteen culture liquid and a plurality of bacterial species. The mangosteen culture solution includes mangosteen and water, and the ratio of mangosteen to water is 1:2-5. Compared with the mangosteen culture medium, the multiple strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria.

綜上所述，根據本發明任一實施例的山竹發酵液，其可製備美肌及/或減脂的組合物。換言之，前述之組合物具有下列一種或多種功能：提升抗氧化活性、抑制糖化終產物形成、抑制酪胺酸酶形成、抑制脂肪累積、減少受體的體脂肪以及改善肌膚狀況。To sum up, according to the mangosteen fermentation broth of any embodiment of the present invention, a composition for beautifying skin and/or reducing fat can be prepared. In other words, the aforementioned composition has one or more of the following functions: enhancing antioxidant activity, inhibiting glycation end product formation, inhibiting tyrosinase formation, inhibiting fat accumulation, reducing receptor body fat, and improving skin condition.

關於本文中所使用之濃度符號「%」通常是指重量百分濃度，而濃度符號「vol%」通常是指體積百分濃度。關於本文中所使用之「山竹」通常是指山竹果實。The concentration symbol "%" as used herein generally refers to weight percent concentration, while the concentration symbol "vol%" generally refers to volume percent concentration. As used herein, "mangosteen" generally refers to mangosteen fruit.

在一些實施例中，山竹發酵液是由山竹培養液與及複數菌種進行一發酵程序所得。其中，山竹培養液包括山竹及水。在山竹培養液中，山竹與水的比例為1:2-5。在發酵程序中，相對於山竹培養液，此些菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。In some embodiments, the mangosteen fermentation broth is obtained by performing a fermentation process with the mangosteen culture broth and multiple strains. Wherein, the mangosteen culture solution includes mangosteen and water. In the mangosteen culture medium, the ratio of mangosteen to water is 1:2-5. In the fermentation procedure, these strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria relative to the mangosteen broth.

在一些實施例中，酵母菌可以是啤酒酵母（Saccharomyces cerevisiae）。在一些實施例中，乳酸菌可以是胚芽乳酸桿菌（Lactobacillus plantarum）或植物乳桿菌。在一些實施例中，醋酸菌可以是乙酸醋酸菌（Acetobacter aceti）。In some embodiments, the yeast may be Saccharomyces cerevisiae. In some embodiments, the lactic acid bacteria may be Lactobacillus plantarum or Lactobacillus plantarum. In some embodiments, the acetic acid bacteria may be Acetobacter aceti.

在一些實施例中，在發酵程序中，先添加0.01%-0.5%的酵母菌至山竹培養液內，並將山竹培養液與酵母菌進行發酵1日至3日以形成第一初發酵液。換言之，0.01%-0.5%的酵母菌與山竹培養液混合成的第一混合液進行發酵1日至3日以形成第一初發酵液。在一些實施例中，第一混合液是在28℃-37℃下進行發酵。In some embodiments, in the fermentation process, 0.01%-0.5% yeast is added to the mangosteen culture solution, and the mangosteen culture solution and the yeast are fermented for 1 to 3 days to form a first initial fermentation solution. In other words, the first mixed solution obtained by mixing 0.01%-0.5% of the yeast with the mangosteen culture solution is fermented for 1 to 3 days to form the first initial fermentation solution. In some embodiments, the first mixed liquor is fermented at 28°C-37°C.

於第一初發酵液形成後，再添加0.01%-0.25%乳酸菌至第一初發酵液內，並將第一初發酵液與乳酸菌進行發酵1日至5日以形成第二初發酵液。換言之，0.01%-0.25%乳酸菌與第一初發酵液混合成的第二混合液進行發酵1日至5日以形成第二初發酵液。在一些實施例中，第二混合液是在28℃-37℃下進行發酵。After the first primary fermentation broth is formed, 0.01%-0.25% lactic acid bacteria are added to the first primary fermentation broth, and the first primary fermentation broth and lactic acid bacteria are fermented for 1 to 5 days to form a second primary fermentation broth. In other words, the second mixed liquor obtained by mixing 0.01%-0.25% lactic acid bacteria and the first primary fermentation liquor is fermented for 1 to 5 days to form the second primary fermentation liquor. In some embodiments, the second mixed liquor is fermented at 28°C-37°C.

於第二初發酵液形成後，再添加1%-15%的醋酸菌至第二初發酵液內，並將第二初發酵液與醋酸菌進行發酵3日至10日以形成第三初發酵液。換言之，1%-15%的醋酸菌與第二初發酵液混合成的第三混合液進行發酵3日至10日以形成第三初發酵液。在一些實施例中，第三混合液是在28℃-37℃下進行發酵。After the second initial fermentation broth is formed, 1%-15% of acetic acid bacteria are added to the second initial fermentation broth, and the second initial fermentation broth and acetic bacteria are fermented for 3 to 10 days to form a third initial fermentation liquid. In other words, the third mixed liquor obtained by mixing 1%-15% of acetic bacteria and the second primary fermentation broth is fermented for 3 to 10 days to form the third primary fermentation broth. In some embodiments, the third mixed liquor is fermented at 28°C-37°C.

於第三初發酵液形成後，過濾第三初發酵液以得到山竹發酵液。在第一示範例中，第三初發酵液的過濾步驟包括以200目數至400目數的網孔的濾網過濾第三初發酵液。在第二示範例中，第三初發酵液的過濾步驟包括在40℃至70℃下減壓濃縮及以200目數至400目數的網孔的濾網過濾第三初發酵液。在第三示範例中，第三初發酵液的過濾步驟包括在40℃至70℃下減壓濃縮及以200目數至400目數的網孔的濾網過濾第三初發酵液以得到一發酵原液，以及調整發酵原液的糖度（Degrees Brix）以形成山竹發酵液。After the third primary fermentation broth is formed, the third primary fermentation broth is filtered to obtain mangosteen fermentation broth. In the first exemplary example, the filtering step of the third primary fermentation broth includes filtering the third primary fermentation broth with a filter screen having a mesh size of 200 to 400 mesh. In the second exemplary example, the filtering step of the third primary fermentation broth includes concentrating under reduced pressure at 40°C to 70°C and filtering the third primary fermentation broth with a mesh of 200 to 400 mesh. In the third exemplary example, the filtering step of the third primary fermentation broth includes concentrating under reduced pressure at 40°C to 70°C and filtering the third primary fermentation broth with a mesh of 200 to 400 mesh to obtain a Fermentation stock solution, and adjusting the sugar content (Degrees Brix) of fermentation stock solution to form mangosteen fermentation stock.

在一些實施例中，可透過添加55%-70%的賦形劑（excipient）來調整發酵原液的糖度。在一些實施例中，用以調整糖度的賦形劑可為異麥芽寡糖。In some embodiments, the sugar content of the fermentation stock can be adjusted by adding 55%-70% excipients. In some embodiments, the excipient used to adjust the sugar content may be isomalt-oligosaccharide.

在一些實施例中，山竹發酵液的pH值為3.7±1.0，且山竹發酵液的糖度為40±2。In some embodiments, the pH of the mangosteen fermentation broth is 3.7±1.0, and the Brix of the mangosteen fermentation broth is 40±2.

在一些實施例中，山竹發酵液的多酚含量為691ppm。In some embodiments, the polyphenol content of the mangosteen fermentation broth is 691 ppm.

在一些實施例中，山竹培養液的製備方法如下。首先，將山竹打碎以形成山竹顆粒，然後將山竹顆粒與水以1：2-5的比例混合以得到原料混合液。接著，將得到的原料混合液進行一滅菌程序以得到山竹培養液（亦可稱之為山竹萃取液）。In some embodiments, the preparation method of mangosteen culture solution is as follows. First, the mangosteen is broken to form mangosteen particles, and then the mangosteen particles are mixed with water in a ratio of 1:2-5 to obtain a raw material mixed solution. Next, the obtained raw material mixture is subjected to a sterilization procedure to obtain a mangosteen culture solution (also referred to as a mangosteen extract).

在一些實施例中，於此所選用的山竹可為帶殼的全果。換言之，山竹全果連果殼一起打碎成山竹顆粒。在一些實施例中，於此所選用的山竹可為成熟可食用的山竹果實。在一些實施例中，山竹顆粒的粒徑可為12mm（公厘）以下。In some embodiments, the mangosteen selected herein may be the whole fruit in the shell. In other words, the whole mangosteen fruit is broken into mangosteen particles together with the husk. In some embodiments, the mangosteen selected herein may be a ripe edible mangosteen fruit. In some embodiments, the particle size of the mangosteen particles may be less than 12 mm (millimeters).

在一些實施例中，原料混合液的滅菌程序可為將原料混合液在80℃至100℃下滅菌0.2小時至1小時，並將滅菌後的原料混合液冷卻至室溫（即25℃至30℃）以形成山竹培養液。在一些實施例中，滅菌後的原料混合液可採取自然降溫的方式冷卻至室溫。In some embodiments, the sterilization procedure of the raw material mixture may be sterilizing the raw material mixture at 80° C. to 100° C. for 0.2 hour to 1 hour, and cooling the sterilized raw material mixture to room temperature (ie, 25° C. to 30° C.). ℃) to form a mangosteen culture solution. In some embodiments, the sterilized raw material mixture can be cooled to room temperature by natural cooling.

在一些實施例中，山竹發酵液具有美肌及/或減脂之作用。在一些實施例中，山竹發酵液能透過減少一受體的體脂肪來達成減脂的作用。在一些實施例中，山竹發酵液能透過改善一受體的肌膚狀況來達成美肌的作用。在一些示範例中，改善受體的肌膚狀況可為提升受體的肌膚含水量、降低受體的深層斑、減少受體的皺紋、減少受體的肌膚紋理或其組合。在一些實施例中，山竹發酵液能透過下列一種或多種細胞層面的作用來達成美肌及/或減脂之作用：提升抗氧化活性、抑制糖化終產物形成、抑制酪胺酸酶形成、以及抑制脂肪累積。其中，受體可為人。In some embodiments, the mangosteen fermentation broth has skin beautifying and/or fat reducing effects. In some embodiments, the mangosteen fermentation broth can achieve fat reduction by reducing body fat in a receptor. In some embodiments, the mangosteen fermentation liquid can achieve the effect of skin beautification by improving the skin condition of a receptor. In some examples, improving the subject's skin condition can be increasing the subject's skin moisture content, reducing the subject's deep spots, reducing the subject's wrinkles, reducing the subject's skin texture, or a combination thereof. In some embodiments, mangosteen fermentation broth can achieve skin beautification and/or fat reduction through one or more of the following cellular-level actions: enhancing antioxidant activity, inhibiting glycation end product formation, inhibiting tyrosinase formation, and inhibiting Fat accumulation. Wherein, the receptor can be human.

在一些實施例中，山竹發酵液能用於製備用以提升抗氧化活性的組合物。In some embodiments, mangosteen fermentation broth can be used to prepare compositions for enhancing antioxidant activity.

在一些實施例中，山竹發酵液能用於製備用以抑制糖化終產物形成的組合物。In some embodiments, mangosteen fermentation broth can be used to prepare a composition for inhibiting the formation of saccharification end products.

在一些實施例中，山竹發酵液能用於製備用以抑制酪胺酸酶形成的組合物。In some embodiments, mangosteen fermentation broth can be used to prepare a composition for inhibiting tyrosinase formation.

在一些實施例中，山竹發酵液能用於製備用以抑制脂肪累積的組合物。In some embodiments, mangosteen fermentation broth can be used to prepare a composition for inhibiting fat accumulation.

在一些實施例中，山竹發酵液能用於製備用以減少一受體的體脂肪的組合物。In some embodiments, mangosteen fermentation broth can be used to prepare a composition for reducing body fat in a recipient.

在一些實施例中，山竹發酵液能用於製備用以改善肌膚狀況的組合物。其中，改善肌膚狀況可為提升肌膚含水量、降低深層斑、減少皺紋、減少肌膚紋理或其組合。In some embodiments, mangosteen fermentation broth can be used to prepare compositions for improving skin condition. Among them, improving skin condition can be increasing skin moisture content, reducing deep spots, reducing wrinkles, reducing skin texture, or a combination thereof.

在一些實施例中，前述之任一組合物可為醫藥品。換言之，此醫藥品包含有效含量的山竹發酵液。In some embodiments, any of the foregoing compositions can be a pharmaceutical. In other words, the medicinal product contains mangosteen fermentation broth in an effective amount.

在一些實施例中，前述之醫藥品可利用熟習此技藝者所詳知的技術而被製造成適合於經腸道地、非經腸道地（parenterally）、口服地、或局部地（topically）投藥劑型。In some embodiments, the aforementioned pharmaceutical products can be manufactured to be suitable for parenterally, parenterally, orally, or topically using techniques well known to those skilled in the art Dosage form.

在一些實施例中，經腸道或口服的投藥劑型可為，但不限於，錠劑（tablet）、片劑（troche）、***錠（lozenge）、丸劑（pill）、膠囊（capsule）、分散性粉末（dispersible powder）或細顆粒（granule）、溶液、懸浮液（suspension）、乳劑（emulsion）、糖漿（syrup）、酏劑（elixir）、濃漿（slurry）或類似之物。在一些實施例中，非經腸道地或局部地投藥劑型可為，但不限於，注射品（injection）、無菌的粉末（sterile powder）、外部製劑（external preparation）或類似之物。在一些實施例中，注射品的投藥方式可為皮下注射（subcutaneous injection）、表皮內注射（intraepidermal injection）、皮內注射（intradermal injection）或病灶內注射（intralesional injection）。In some embodiments, the dosage form for parenteral or oral administration can be, but is not limited to, a tablet, troche, lozenge, pill, capsule , dispersible powder or granule, solution, suspension, emulsion, syrup, elixir, slurry or the like. In some embodiments, the dosage form for parenteral or topical administration can be, but is not limited to, an injection, sterile powder, external preparation, or the like. In some embodiments, the injection can be administered by subcutaneous injection, intraepidermal injection, intradermal injection or intralesional injection.

在一些實施例中，前述之醫藥品可包含被廣泛地使用於藥物製造技術之醫藥上可接受的載劑（pharmaceutically acceptable carrier）。在一些實施例中，醫藥上可接受的載劑可為下列載劑中一種或多種：溶劑（solvent）、緩衝液（buffer）、乳化劑（emulsifier）、懸浮劑（suspending agent）、分解劑（decomposer）、崩解劑（disintegrating agent）、分散劑（dispersing agent）、黏結劑（binding agent）、賦形劑、安定劑（stabilizing agent）、螯合劑（chelating agent）、稀釋劑（diluent）、膠凝劑（gelling agent）、防腐劑（preservative）、潤濕劑（wetting agent）、潤滑劑（lubricant）、吸收延遲劑（absorption delaying agent）、脂質體（liposome）以及類似之物。關於選用之載劑的種類與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。在一些實施例中，作為醫藥上可接受的載劑的溶劑可為水、生理鹽水（normal saline）、磷酸鹽緩衝液（phosphate buffered saline，PBS）、或含有醇的水性溶液（alcohol containing aqueous solution ）。In some embodiments, the aforementioned pharmaceutical product may comprise a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing techniques. In some embodiments, the pharmaceutically acceptable carrier can be one or more of the following carriers: solvent, buffer, emulsifier, suspending agent, disintegrant ( decomposer), disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent, glue Gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes, and the like. Regarding the type and quantity of the carrier selected, it falls within the scope of the professional quality and routine skills of those who are familiar with the technology. In some embodiments, the solvent as a pharmaceutically acceptable carrier may be water, normal saline, phosphate buffered saline (PBS), or an alcohol containing aqueous solution ).

在一些實施例中，前述之任一組合物可為食用組合物。換言之，食用組合物包含特定含量的山竹發酵液。在一些實施例中，前述之食用組合物可為食品產品或食品添加物（food additive）。在一些實施例中，食品產品可為但不限於：飲料（beverages）、發酵食品（fermented foods）、烘培產品（bakery products）、健康食品（health foods）或膳食補充品（dietary supplements）。In some embodiments, any of the foregoing compositions may be edible compositions. In other words, the edible composition contains a certain amount of mangosteen fermentation broth. In some embodiments, the aforementioned edible composition may be a food product or a food additive. In some embodiments, the food products can be, but are not limited to, beverages, fermented foods, bakery products, health foods, or dietary supplements.

在一些實施例中，前述之食用組合物可以口服方式施予受體。其中，食用組合物的型態可為粉末、顆粒、溶液、膠體或膏體。In some embodiments, the aforementioned edible compositions can be administered to a recipient orally. Wherein, the form of the edible composition can be powder, granule, solution, colloid or paste.

在一些實施例中，前述之任一組合物可為化妝品或保養品。換言之，化妝品或保養品包含特定含量的山竹發酵液。In some embodiments, any of the foregoing compositions can be a cosmetic or skin care product. In other words, cosmetics or skin care products contain a specific amount of mangosteen fermentation broth.

在一些實施例中，前述之化妝品或保養品可為下列任一種型態：化妝水、凝膠、凍膜、泥膜、乳液、乳霜、唇膏、粉底、粉餅、蜜粉、卸妝油、卸妝乳、洗面乳、沐浴乳、洗髮精、護髮乳、防曬乳、護手霜、指甲油、香水、精華液及面膜。在一些實施例中，前述之化妝品或保養品可視需要更包含外用品可接受成分。在一些實施例中，外用品可接受成分可例如為乳化劑、滲透促進劑、軟化劑、溶劑、賦型劑、抗氧化劑、或其組合。In some embodiments, the aforementioned cosmetics or skin care products can be in any of the following forms: lotion, gel, jelly film, mud film, lotion, cream, lipstick, foundation, pressed powder, powder, makeup remover, makeup remover Milk, facial cleanser, body wash, shampoo, conditioner, sunscreen, hand cream, nail polish, perfume, serum and mask. In some embodiments, the aforementioned cosmetics or skin care products may further include externally acceptable ingredients as needed. In some embodiments, topical acceptable ingredients may be, for example, emulsifiers, penetration enhancers, emollients, solvents, excipients, antioxidants, or combinations thereof.

例一：山竹發酵液的製備Example 1: Preparation of mangosteen fermentation broth

首先將山竹全果（含殼）打碎成粒徑12mm以下的山竹顆粒。將山竹顆粒與水以1:3的比例混合均勻以得到原料混合液。然後，將原料混合液在約100℃下滅菌0.5小時，並將滅菌後的原料混合液冷卻至約30℃以得到山竹培養液。First, the whole mangosteen fruit (including the shell) is broken into mangosteen particles with a particle size of less than 12mm. The mangosteen granules and water are uniformly mixed in a ratio of 1:3 to obtain a raw material mixed solution. Then, the raw material mixture was sterilized at about 100° C. for 0.5 hours, and the sterilized raw material mixture was cooled to about 30° C. to obtain a mangosteen culture solution.

於山竹培養液中殖入0.1%啤酒酵母（購自食品工業發展研究所生物資源保存及研究中心(BCRC)，寄存編號BCRC20271）並在約30℃下發酵1天，以得到第一初發酵液。接著，於第一初發酵液中殖入0.05%胚芽乳酸桿菌（購自BCRC，寄存編號BCRC910760）並在約30℃下發酵1天，以得到第二初發酵液。最後，於第二初發酵液中殖入10%乙酸醋酸菌（購自BCRC，寄存編號BCRC11688）並在約30℃下發酵5天，以得到第三初發酵液。0.1% brewer's yeast (purchased from the Biological Resource Conservation and Research Center (BCRC), Institute of Food Industry Development, accession number BCRC20271) was propagated into the mangosteen culture solution and fermented at about 30°C for 1 day to obtain the first primary fermentation solution . Next, 0.05% Lactobacillus embryonicum (purchased from BCRC, accession number BCRC910760) was propagated into the first primary fermentation broth and fermented at about 30° C. for 1 day to obtain a second primary fermentation broth. Finally, 10% acetic acid bacteria (purchased from BCRC, accession number BCRC11688) were propagated into the second primary fermentation broth and fermented at about 30° C. for 5 days to obtain a third primary fermentation broth.

再將第三初發酵液在約60℃下進行減壓濃縮並以目數的網孔的濾網過濾，以得到發酵原液。最後，添加60%異麥芽寡糖至發酵原液後進行滅菌，以得到山竹發酵液。The third primary fermentation broth is then concentrated under reduced pressure at about 60° C. and filtered through a mesh filter to obtain a fermentation stock solution. Finally, 60% isomalt oligosaccharide is added to the fermentation stock solution and then sterilized to obtain a mangosteen fermentation broth.

於此，分別對山竹培養液、發酵原液以及山竹發酵液進行糖度檢測。其中，山竹培養液的糖度約為10.6，發酵原液的糖度約為3.9，以及山竹發酵液的糖度約為40。Here, the sugar content of the mangosteen culture solution, the fermentation stock solution, and the mangosteen fermentation broth was detected respectively. Among them, the sugar content of the mangosteen culture liquid is about 10.6, the sugar content of the fermentation stock solution is about 3.9, and the sugar content of the mangosteen fermentation liquid is about 40.

例二：總多酚含量測試Example 2: Total polyphenol content test

秤取10.0mg的沒食子酸（Gallic acid）置於10mL容量瓶中，然後以水（H2 O）定量至10mL，以得到沒食子酸的儲備溶液（stock solution）。將沒食子酸的儲備溶液稀釋10倍，即100μL沒食子酸的儲備溶液加900μL的水，以得到100μg/mL沒食子酸的初始溶液（即含1000ppm的沒食子酸）。然後，依據下表一配置0μg/mL、20μg/mL、40μg/mL、60μg/mL、80μg/mL、及100μg/mL之沒食子酸的標準溶液，並分別取100μL之各濃度的標準溶液至玻璃試管中。加入500μL之福林酚試劑（Folin-Ciocalteu's phenol reagent，購自Merck）至各玻璃試管內與標準溶液混合均勻並靜置3分鐘後，再加入400μL之7.5%碳酸鈉混合均勻後反應30分鐘以得到標準反應溶液。取200μL之標準反應溶液至96孔板中，並測量其在750nm下之吸光值，以獲得標準曲線。10.0 mg of gallic acid was weighed into a 10 mL volumetric flask, and then quantified to 10 mL with water (H 2 O) to obtain a stock solution of gallic acid. Dilute the stock solution of gallic acid by a factor of 10, i.e., 100 μL of the stock solution of gallic acid plus 900 μL of water, to obtain an initial solution of 100 μg/mL gallic acid (i.e., containing 1000 ppm of gallic acid). Then, prepare standard solutions of gallic acid of 0 μg/mL, 20 μg/mL, 40 μg/mL, 60 μg/mL, 80 μg/mL, and 100 μg/mL according to Table 1, and take 100 μL of the standard solutions of each concentration. into a glass test tube. Add 500 μL of Folin-Ciocalteu's phenol reagent (purchased from Merck) to each glass test tube and mix it with the standard solution and let it stand for 3 minutes, then add 400 μL of 7.5% sodium carbonate, mix well, and react for 30 minutes. A standard reaction solution was obtained. Take 200 μL of the standard reaction solution into a 96-well plate, and measure its absorbance at 750 nm to obtain a standard curve.

表一 標準溶液（μg/mL） 0 20 40 60 80 100 初始溶液（μL） 0 20 40 60 80 100 水（μL） 100 80 60 40 20 0 Table I Standard solution (μg/mL) 0 20 40 60 80 100 Initial solution (μL) 0 20 40 60 80 100 water (μL) 100 80 60 40 20 0

分別以例一中所得到的山竹培養液與發酵原液作為樣本。將各樣本取100mL到玻璃試管中。接著，加入500μL之福林酚試劑至玻璃試管中與樣本混合均勻並靜置3分鐘後，再加入400μL之7.5%碳酸鈉混合均勻後反應30分鐘以得到待測反應溶液。將裝有待測反應溶液的玻璃試管進行震盪以確保無氣泡後，取200μL之待測反應溶液至96孔板中，並測量待測反應溶液於750nm下之吸光值。The mangosteen culture solution and fermentation stock solution obtained in Example 1 were taken as samples respectively. 100 mL of each sample was taken into a glass test tube. Next, add 500 μL of Folin phenol reagent to the glass test tube and mix with the sample evenly and let it stand for 3 minutes, then add 400 μL of 7.5% sodium carbonate, mix well, and react for 30 minutes to obtain the reaction solution to be tested. After shaking the glass test tube containing the reaction solution to be tested to ensure no air bubbles, take 200 μL of the reaction solution to be tested into a 96-well plate, and measure the absorbance of the reaction solution to be tested at 750 nm.

接著，各樣本對應的待測反應溶液的吸光值先除以樣本的糖度，再利用標準曲線以內插法換算成總多酚含量。於此，可得到山竹培養液的總多酚含量為334ppm及山竹發酵液的總多酚含量為691ppm，如圖1所示。由此可知，山竹透過微生物發酵後，可增加總多酚含量2.1倍。即，相對於山竹培養液，山竹酵素液能提升抗氧化活性。Next, the absorbance value of the reaction solution to be tested corresponding to each sample is firstly divided by the sugar content of the sample, and then converted into the total polyphenol content by the interpolation method of the standard curve. Here, the total polyphenol content of the mangosteen culture liquid was 334 ppm and the total polyphenol content of the mangosteen fermentation liquid was 691 ppm, as shown in FIG. 1 . It can be seen that the total polyphenol content of mangosteen can be increased by 2.1 times after microbial fermentation. That is, compared with the mangosteen culture liquid, the mangosteen enzyme liquid can enhance the antioxidant activity.

例三：抗醣化測試Example 3: Anti-glycation test

以200mM磷酸鈉緩衝液（Sodium phosphate buffer，pH7.4）、疊氮化鈉（Sodium azide，NaN3 ）與牛血清白蛋白（Bovine serum albumin，BSA，品牌：Gibco）配置含有0.06%NaN3 的60mg/mL BSA溶液。0.06% NaN 3 was prepared with 200 mM sodium phosphate buffer (Sodium phosphate buffer, pH 7.4), sodium azide (NaN 3 ) and bovine serum albumin (BSA, brand: Gibco). 60 mg/mL BSA solution.

以200mM磷酸鈉緩衝液與D果糖（D-(-)-Fructose，C6 H12 O6 ）配置1.5M D-fructose溶液。A 1.5 M solution of D-fructose was prepared in 200 mM sodium phosphate buffer and D-fructose (D-(-)-Fructose, C 6 H 12 O 6 ).

以200mM磷酸鈉緩衝液與氨基胍鹽酸鹽（Aminoguanidine hydrochloride，AG，CH6 N4 •HCl）配置3mM AG溶液。A 3 mM AG solution was prepared with 200 mM sodium phosphate buffer and aminoguanidine hydrochloride (AG, CH 6 N 4 •HCl).

取0.25mL例一中所得到的山竹發酵液加入0.25mL BSA溶液與D-fructose溶液並均勻混合以得到實驗組的待測溶液。Take 0.25 mL of the mangosteen fermentation broth obtained in Example 1, add 0.25 mL of BSA solution and D-fructose solution and mix them uniformly to obtain the test solution of the experimental group.

取0.25mL之3mM AG溶液加入0.25mL BSA溶液與D-fructose溶液並均勻混合以得到控制組的待測溶液。0.25mL of 3mM AG solution was added to 0.25mL of BSA solution and D-fructose solution and mixed uniformly to obtain the test solution of the control group.

取0.1mL各組別的待測溶液作為各組別的零點溶液。使用螢光分光光度計（Thermo Fisher Scientific‎）對0.1mL各組別的零點溶液以360nm之激發光以及460nm之放射光測定其螢光值，以得到反應前之零點之螢光值。Take 0.1 mL of the solution to be tested in each group as the zero point solution for each group. Use a spectrophotometer (Thermo Fisher Scientific) to measure the fluorescence values of 0.1 mL of each group of zero-point solutions with excitation light of 360 nm and emission light of 460 nm to obtain the zero-point fluorescence value before the reaction.

取0.45mL各組別的待測溶液於50℃下培養24小時，以得到各組別的終點溶液。取0.1mL各組別的終點溶液並使用螢光分光光度計對0.1mL各組別的終點溶液以360nm之激發光以及460nm之放射光測定其螢光值，以得到反應之終點之螢光值。Take 0.45mL of the test solution of each group and incubate at 50°C for 24 hours to obtain the end point solution of each group. Take 0.1mL of the end point solution of each group and use a spectrophotometer to measure the fluorescence value of 0.1mL of the end point solution of each group with excitation light of 360nm and emission light of 460nm to obtain the fluorescence value of the end point of the reaction .

然後根據下列公式(1)計算各組別的相對糖化終產物（Advanced Glycation End products，AGEs）的形成量（%），以得知其抗醣化活性（Antiglycative activity）。換言之，於此，是將控制組的AGEs形成量視為1（即控制組的相對AGEs形成量為100%）來計算各組別的相對AGEs形成量（%）。Then, the relative formation amount (%) of advanced glycation end products (AGEs) of each group was calculated according to the following formula (1) to know its antiglycative activity. In other words, here, the relative amount (%) of AGEs formed in each group was calculated by considering the amount of AGEs formed in the control group as 1 (ie, the relative amount of AGEs formed in the control group was 100%).

AGEs形成量(％)＝

Figure 02_image001
(1)Amount of AGEs formed (%) =
Figure 02_image001
(1)

其中，Fluorescence sample24hr 代表實驗組的終點之螢光值，Fluorescence sample0hr 代表實驗組的零點之螢光值，Fluorescence control24hr 代表控制組的終點之螢光值，Fluorescence control0hr 代表控制組的零點之螢光值。Among them, Fluorescence sample 24hr represents the fluorescence value of the endpoint of the experimental group, Fluorescence sample 0hr represents the fluorescence value of the zero point of the experimental group, Fluorescence control 24hr represents the fluorescence value of the endpoint of the control group, and Fluorescence control 0hr represents the zero point of the control group. Fluorescence value.

參照圖2，相較於控制組，實驗組明顯減少70%的糖化終產物的形成量。由此可知，山竹發酵液能有效抑制糖化終產物的形成，即具有抗醣化的作用。Referring to Figure 2, compared with the control group, the experimental group significantly reduced the formation of glycation end products by 70%. It can be seen that the mangosteen fermentation broth can effectively inhibit the formation of end products of saccharification, that is, it has the effect of anti-glycation.

例四：黑色素含量檢測Example 4: Detection of melanin content

於此，所使用的細胞培養基為添加有1vol%盤尼西林-鏈黴素（penicillin/streptomycin，品牌：Gibco）及10vol%胎牛血清（fetal bovine serum，FBS，品牌：Gibco）之杜貝可氏改良的依格氏培養基（Dulbecco’s Modified Eagle’s Medium，DMEM，品牌：Gibco）。Herein, the cell culture medium used was Dubex's modification supplemented with 1 vol% penicillin/streptomycin (Gibco, brand: Gibco) and 10 vol% fetal bovine serum (FBS, brand: Gibco). Eagle's medium (Dulbecco's Modified Eagle's Medium, DMEM, brand: Gibco).

首先，以每孔1.5×105 個細胞的細胞數，將小鼠黑色素瘤細胞株B16F10（購自美國典型培養物保存中心(ATCC)，編號CRL-6475）接種於含有3mL細胞培養基的6孔培養盤的各孔中，並置於37°C下培養24小時。First, the mouse melanoma cell line B16F10 (purchased from the American Type Culture Collection (ATCC), No. CRL-6475) was inoculated into 6 wells containing 3 mL of cell culture medium at a cell number of 1.5 × 10 5 cells per well. in each well of the plate and incubated at 37°C for 24 hours.

在培養24小時後，將B16F10細胞分成4個組別：二個實驗組（即實驗組A與實驗組B）、一個對照組以及一個控制組。移除各組別的細胞培養基，並更換成每孔3mL實驗培養基，然後置於37°C下接續培養48小時。其中，實驗組A的實驗培養基為含有0.125vol%例一中所得到的山竹發酵液的細胞培養基。實驗組B的實驗培養基為含有0.125vol%例一中所得到的山竹培養液的細胞培養基。對照組的實驗培養基為含有0.125mg/mL麴酸（kojic acid）的細胞培養基。控制組的實驗培養基為單純的細胞培養基（即不含山竹發酵液、不含山竹培養液，也不含麴酸）。After 24 hours of culture, B16F10 cells were divided into 4 groups: two experimental groups (ie, experimental group A and experimental group B), a control group and a control group. The cell culture medium of each group was removed and replaced with 3 mL of experimental medium per well, and then placed at 37°C for 48 hours. Wherein, the experimental medium of experimental group A was a cell culture medium containing 0.125 vol% of the mangosteen fermentation broth obtained in Example 1. The experimental medium of experimental group B was a cell culture medium containing 0.125 vol% of the mangosteen culture solution obtained in Example 1. The experimental medium of the control group was cell culture medium containing 0.125 mg/mL kojic acid. The experimental medium of the control group was a simple cell culture medium (ie, no mangosteen fermentation broth, no mangosteen culture broth, and no koji acid).

於培養48小時後，移除各孔中的實驗培養基並以1倍（1x）的磷酸鹽緩衝液（phosphate buffered saline，PBS，品牌：Gibco）潤洗二次。於沖洗後，將胰蛋白酶（trypsin）加入至各孔中以處理細胞3分鐘。於3分鐘處理後，將各孔的懸浮的細胞個別收集於15mL離心管中，接而以400xg離心5分鐘以分離細胞沉澱物（cell pellet）與上清液。透過1xPBS再懸浮細胞沉澱物及離心反覆進行二次後，以200μL的1xPBS再懸浮細胞沉澱物，以得到細胞溶液。接著，將細胞溶液於液態氮中放置10分鐘，接而於室溫下靜置30分鐘進行解凍。在解凍完全之後，各離心管以12,000xg離心30分鐘。於30分鐘離心後，移除各離心管中上清液並添加入120μL 1N NaOH（配於ddH2 O）以與各離心管中的沉澱物進行混合。在混合均勻之後，將含有混合溶液的各離心管於60℃乾浴槽中靜置1小時。之後，從各離心管中取100μL混合溶液至96孔培養盤中並於450nm的波長下以ELISA（enzyme-linked immunosorbent assay，酵素結合免疫吸附法）讀取儀（廠牌：BioTek）來讀取96孔培養盤中各孔的吸光值（OD450）。After 48 hours of incubation, the experimental medium in each well was removed and rinsed twice with 1x (1x) phosphate buffered saline (PBS, brand: Gibco). After washing, trypsin was added to each well to treat the cells for 3 minutes. After 3 minutes of treatment, the suspended cells in each well were individually collected in 15 mL centrifuge tubes, and then centrifuged at 400 x g for 5 minutes to separate the cell pellet and the supernatant. After the cell pellet was resuspended in 1xPBS and centrifugation was repeated twice, the cell pellet was resuspended with 200 μL of 1xPBS to obtain a cell solution. Next, the cell solution was placed in liquid nitrogen for 10 minutes, and then stood at room temperature for 30 minutes to thaw. After complete thawing, each centrifuge tube was centrifuged at 12,000 xg for 30 minutes. After 30 minutes of centrifugation, the supernatant from each tube was removed and 120 μL of 1N NaOH (in ddH 2 O) was added to mix with the pellet in each tube. After mixing uniformly, each centrifuge tube containing the mixed solution was left to stand in a 60°C dry bath for 1 hour. Then, take 100 μL of the mixed solution from each centrifuge tube into a 96-well culture dish and read it with an ELISA (enzyme-linked immunosorbent assay, enzyme-linked immunosorbent assay) reader (brand: BioTek) at a wavelength of 450 nm. Absorbance value (OD450) of each well in a 96-well plate.

於量測後，藉由將所測得的吸光值代入下列公式(2)而計算出相對黑色素含量（%）。換言之，於此，是將控制組的黑色素含量視為1（即控制組的相對黑色素含量為100%）來計算各組別的相對黑色素含量（%）。並且，各組之間的統計學顯著差異是藉由學生t-試驗（student t-test）來統計分析，如圖3所示。在圖3中，「*」代表在與控制組比較下其p值小於0.05，「**」代表在與控制組比較下其p值小於0.01，「***」代表在與控制組比較下其p值小於0.001，以及「▲▲▲」代表在與對照組比較下其p值小於0.001。After the measurement, the relative melanin content (%) was calculated by substituting the measured absorbance value into the following formula (2). In other words, here, the relative melanin content (%) of each group is calculated by considering the melanin content of the control group as 1 (ie, the relative melanin content of the control group is 100%). Also, statistically significant differences between groups were statistically analyzed by student t-test, as shown in FIG. 3 . In Figure 3, "*" represents that the p-value is less than 0.05 when compared with the control group, "**" represents that the p-value is less than 0.01 when compared with the control group, and "***" represents the comparison with the control group. Its p value is less than 0.001, and "▲▲▲" means its p value is less than 0.001 in comparison with the control group.

相對黑色素含量(%)＝(OD450 sample/OD450 control)×100%     (2)Relative melanin content (%) = (OD450 sample/OD450 control) × 100% (2)

其中，OD450 sample代表欲換算之組別的吸光值，而OD450 control代表控制組的吸光值。Among them, OD450 sample represents the absorbance value of the group to be converted, and OD450 control represents the absorbance value of the control group.

參照圖3，相較於控制組，實驗組A的黑色素含量有顯著地降低，且其可降低21.58%的黑色素生成。並且，相較於對應濃度的麴酸，實驗組A的黑色素含量亦有顯著地降低，且其可降低21.58%的黑色素生成。相較於實驗組B，實驗組A亦可降低1.0%的黑色素生成。由此可知，山竹發酵液能有效抑制黑色素生成，即有效地抑制酪胺酸酶形成，具有美白之功效。Referring to FIG. 3 , compared with the control group, the melanin content of the experimental group A was significantly reduced, and it could reduce the production of melanin by 21.58%. Moreover, compared with the corresponding concentration of koji acid, the melanin content of experimental group A was also significantly reduced, and it could reduce the production of melanin by 21.58%. Compared with the experimental group B, the experimental group A also reduced the production of melanin by 1.0%. It can be seen that the mangosteen fermentation liquid can effectively inhibit the formation of melanin, that is, effectively inhibit the formation of tyrosinase, and has the effect of whitening.

例五：脂肪累積檢測Example 5: Fat accumulation detection

於此，所使用的前脂肪細胞增殖培養基（pre-adipocyte expansion medium）為添加有20vol% FBS（品牌：Gibco）及1vol%盤尼西林-鏈黴素之最低必需培養基α（Minimum Essential Medium Alpha，MEMα，品牌：Gibco)。所使用的分化培養基（differentiation medium）為添加有20vol% FBS（品牌：Gibco）及1vol%盤尼西林-鏈黴素之MEMα（品牌：Gibco)。並且，將油-紅O染色試劑（品牌：Sigma）徹底溶解於100%異丙醇（isopropanol，供應商：ECHO）以配製3mg/mL之油-紅O染色試劑的儲備溶液。為獲得可供使用的油-紅O工作溶液（oil-red O working solution），於使用前即時將油-紅O染色試劑的儲備溶液以二次水（ddH2O）稀釋至濃度1.8mg/mL，即為60%油-紅O染色試劑的儲備溶液。Here, the pre-adipocyte expansion medium (pre-adipocyte expansion medium) used is the minimum essential medium alpha (Minimum Essential Medium Alpha, MEMα, 20vol% FBS (brand name: Gibco) and 1vol% penicillin-streptomycin) supplemented with Brand: Gibco). The differentiation medium used was MEMα (brand: Gibco) supplemented with 20 vol% FBS (brand: Gibco) and 1 vol% penicillin-streptomycin. And, oil-red O staining reagent (brand: Sigma) was completely dissolved in 100% isopropanol (isopropanol, supplier: ECHO) to prepare a 3 mg/mL stock solution of oil-red O staining reagent. To obtain a ready-to-use oil-red O working solution, dilute the stock solution of oil-red O staining reagent with secondary water (ddH2O) to a concentration of 1.8 mg/mL immediately before use, This is a stock solution of 60% Oil-Red O staining reagent.

首先，以每孔8×104 個細胞的細胞數，將小鼠骨髓基質細胞株OP9（購自ATCC，編號CRL-2749）接種於含有500μL前脂肪細胞增殖培養基的24孔培養盤的各孔中，並置於37°C下培養7天。於7天的培養期間，每3天更換一次新鮮的500μL分化培養基。於培養7天後，使用顯微鏡（廠牌：ZEISS）觀察各孔中的細胞內的油滴（lipid droplet）形成以確認細胞完全分化成脂肪細胞，供後續實驗使用。First, the mouse bone marrow stromal cell line OP9 (purchased from ATCC, accession number CRL-2749) was inoculated into each well of a 24-well culture dish containing 500 μL of preadipocyte proliferation medium at a cell number of 8 × 10 4 cells per well. and cultured at 37°C for 7 days. During the 7-day culture period, fresh 500 μL differentiation medium was replaced every 3 days. After 7 days of culture, the formation of lipid droplets in the cells in each well was observed using a microscope (brand: ZEISS) to confirm that the cells were fully differentiated into adipocytes for subsequent experiments.

在培養24小時後，將脂肪細胞分成3個組別：二個實驗組（即實驗組A與實驗組B）以及控制組。移除各組別的分化培養基，並更換成每孔500μL實驗培養基，然後置於37°C下接續培養7天。於7天的培養期間，每3天更換一次新鮮的500μL實驗培養基。其中，實驗組A的實驗培養基為含有0.0625vol%例一中所得到的山竹發酵液的分化培養基。實驗組B的實驗培養基為含有0.0625vol%例一中所得到的山竹培養液的分化培養基。控制組的實驗培養基為單純的分化培養基（即不含山竹發酵液）。After 24 hours of culture, the adipocytes were divided into 3 groups: two experimental groups (ie, experimental group A and experimental group B) and a control group. The differentiation medium of each group was removed and replaced with 500 μL of experimental medium per well, and then cultured at 37°C for 7 days. During the 7-day culture period, fresh 500 μL experimental medium was replaced every 3 days. Wherein, the experimental medium of experimental group A was a differentiation medium containing 0.0625 vol% of the mangosteen fermentation broth obtained in Example 1. The experimental medium of experimental group B was a differentiation medium containing 0.0625 vol% of the mangosteen culture liquid obtained in Example 1. The experimental medium of the control group was a simple differentiation medium (ie, no mangosteen fermentation broth).

接著，移除各孔中的實驗培養基並以1xPBS潤洗二次。繼而，於各孔內添加1mL的10%甲醛（formaldehyde，供應商：ECHO）並於室溫下培養30分鐘，藉以固定細胞。之後，移除各孔內的甲醛並以1mL PBS對各孔潤洗二次。於再次潤洗後，添加1mL的60%異丙醇至每孔中並作用1分鐘。接著，移除異丙醇，再添加1mL油-紅O工作溶液並於室溫下作用1小時。Next, the experimental medium in each well was removed and rinsed twice with IxPBS. Next, 1 mL of 10% formaldehyde (supplier: ECHO) was added to each well and incubated at room temperature for 30 minutes to fix the cells. Afterwards, the formaldehyde in each well was removed and each well was rinsed twice with 1 mL of PBS. After re-rinsing, 1 mL of 60% isopropanol was added to each well and allowed to act for 1 minute. Next, the isopropanol was removed and an additional 1 mL of Oil-Red O working solution was added and allowed to act at room temperature for 1 hour.

於作用1小時候，移除油-紅O工作溶液並以1mL的60%異丙醇快速退染5秒。於退染後，染色後的細胞以1xPBS潤洗後，加入100%異丙醇至各孔中，並置於振盪器（shaker）上反應10分鐘以溶解染劑。然後，從各孔中取100μL前述之溶染劑-異丙醇溶液至96孔培養盤並於510nm的波長下以ELISA讀取儀（廠牌：BioTek）讀取各孔的吸光值（OD510）。After 1 hour of exposure, the Oil-Red O working solution was removed and rapidly destained with 1 mL of 60% isopropanol for 5 seconds. After destaining, the stained cells were rinsed with 1xPBS, 100% isopropanol was added to each well, and placed on a shaker to react for 10 minutes to dissolve the stain. Then, take 100 μL of the aforementioned dye-isopropanol solution from each well to a 96-well culture plate and read the absorbance (OD510) of each well with an ELISA reader (brand: BioTek) at a wavelength of 510 nm. .

於量測後，藉由將所測得的吸光值代入下列公式(3)而計算出相對脂肪油滴量（%）。換言之，於此，是將控制組的脂肪油滴量視為1（即控制組的相對脂肪油滴量為100%）來計算各組別的相對脂肪油滴量（%）。並且，各組之間的統計學顯著差異是藉由學生t-試驗來統計分析，如圖4所示。在圖4中，「**」代表在與控制組比較下其p值小於0.01。After the measurement, the relative fatty oil droplet amount (%) was calculated by substituting the measured absorbance value into the following formula (3). In other words, here, the relative fatty oil droplet amount (%) of each group is calculated by considering the amount of fatty oil droplets in the control group as 1 (ie, the relative amount of fatty oil droplets in the control group is 100%). Also, statistically significant differences between groups were statistically analyzed by Student's t-test, as shown in FIG. 4 . In Figure 4, "**" represents that the p-value is less than 0.01 in comparison with the control group.

相對脂肪油滴量(%)＝(OD510 sample/OD510 control)×100%     (3)Relative fat oil droplet amount (%)=(OD510 sample/OD510 control)×100% (3)

其中，OD510 sample代表欲換算之組別的吸光值，而OD510 control代表控制組的吸光值。Among them, OD510 sample represents the absorbance value of the group to be converted, and OD510 control represents the absorbance value of the control group.

參照圖4，相較於控制組，實驗組A的相對脂肪油滴量有顯著地降低，且其可減少16.9%的油滴量。相較於實驗組B，實驗組A的相對脂肪油滴量亦有明顯下降，且其可減少8.7%的油滴量。由此可知，山竹發酵液能有效地抑制脂肪累積，具有減脂之功效。並且，山竹透過微生物發酵後可能產出較山竹培養液多的減脂活性成分。Referring to FIG. 4 , compared with the control group, the relative fatty oil droplet amount of the experimental group A was significantly reduced, and it could reduce the oil droplet amount by 16.9%. Compared with the experimental group B, the relative amount of fat oil droplets in the experimental group A also decreased significantly, and it could reduce the amount of oil droplets by 8.7%. It can be seen that the mangosteen fermentation liquid can effectively inhibit the accumulation of fat and has the effect of reducing fat. Moreover, mangosteen may produce more fat-reducing active ingredients than mangosteen culture medium after microbial fermentation.

例六：減脂瘦身之人體檢測Example 6: Human body detection for fat loss and slimming

令8位肥胖受試者（即其體脂率大於25%或BMI值大於24）每日飲用一瓶6mL山竹發酵飲料（其含有12vol%例1中所得到的山竹發酵液與88vol%水），連續飲用4週。並且，於飲用前（即第0週）及飲用4週後（即第4週），以體脂計（廠牌：TANITA BC-601FS）測量此些受試者全身體脂率，以及以布尺量測此些受試者的腰圍。並且，第0週的量測結果與第4週的量測結果之間的統計學顯著差異是藉由學生t-試驗來統計分析，如圖5及圖6所示。在圖5及圖6中，「*」代表在與第0週比較下其p值小於0.05。Eight obese subjects (that is, their body fat rate is greater than 25% or BMI value is greater than 24) drink a 6mL bottle of mangosteen fermented beverage (which contains 12vol% of the mangosteen fermented liquid obtained in Example 1 and 88vol% of water) every day. , drink it continuously for 4 weeks. And, before drinking (ie, the 0th week) and after drinking for 4 weeks (ie, the 4th week), the body fat meter (brand: TANITA BC-601FS) was used to measure the total body fat rate of these subjects, and the cloth The waist circumference of these subjects was measured with a ruler. Also, statistically significant differences between the measurement results at week 0 and the measurement results at week 4 were statistically analyzed by Student's t-test, as shown in Figures 5 and 6 . In Figures 5 and 6, "*" represents that the p-value is less than 0.05 in comparison with week 0.

參照圖5及圖6，相比飲用前（第0週），持續4週飲用山竹發酵飲料可使全身體脂率顯著地減少約0.4%，以及使腰圍顯著地減少約2.0公分。由此可知，長期使用山竹發酵液可改善肥胖者的脂肪累積指數，即山竹發酵液具瘦身減脂之功效。Referring to Figures 5 and 6, compared to before consumption (week 0), drinking mangosteen fermented beverage for 4 weeks can significantly reduce the body fat rate by about 0.4%, and the waist circumference by about 2.0 cm. It can be seen that the long-term use of mangosteen fermentation liquid can improve the fat accumulation index of obese people, that is, mangosteen fermentation liquid has the effect of slimming and reducing fat.

例七：美肌之人體檢測Example 7: Human body detection for skin beauty

令8位胖受試者每日飲用一瓶6mL山竹發酵飲料（其含有12vol%例1中所得到的山竹發酵液與88vol%水），連續飲用6週。並且，於飲用前（即第0週）及飲用6週後（即第6週），以VISIA肌膚檢測儀（VISIA Complexion Analysis System，購自美國Canfield公司）及皮膚表面濕度測試儀（Corneometer CM825，購自德國C+K公司）檢測肌膚狀況。於此，以VISIA肌膚檢測儀量測肌膚深層斑點（褐斑）、肌膚皺紋及肌膚紋理，並且以皮膚表面濕度測試儀量測肌膚含水量。Eight obese subjects were asked to drink a 6 mL bottle of mangosteen fermented beverage (containing 12 vol% of the mangosteen fermented liquid obtained in Example 1 and 88 vol% of water) every day for 6 weeks. In addition, before drinking (that is, the 0th week) and after 6 weeks of drinking (that is, the 6th week), use a VISIA skin detector (VISIA Complexion Analysis System, purchased from Canfield, USA) and a skin surface humidity tester (Corneometer CM825, Purchased from C+K, Germany) to detect skin condition. Here, the VISIA skin tester is used to measure deep skin spots (brown spots), skin wrinkles and skin texture, and the skin moisture content is measured by the skin surface humidity tester.

於量測後，將第0週之肌膚狀況作為基準（即第0週之相對肌膚狀況為100%），計算第6週的相對肌膚狀況（%）。並且，第0週的相對肌膚狀況與第6週的相對肌膚狀況之間的統計學顯著差異是藉由學生t-試驗來統計分析，如圖7至圖10所示。在圖7至圖10中，「*」代表在與第0週比較下其p值小於0.05。After the measurement, the skin condition of the 0th week was used as the benchmark (that is, the relative skin condition of the 0th week was 100%), and the relative skin condition (%) of the 6th week was calculated. Also, the statistically significant difference between the relative skin condition at week 0 and the relative skin condition at week 6 was statistically analyzed by Student's t-test, as shown in Figures 7-10. In Figures 7 to 10, "*" represents a p-value of less than 0.05 in comparison with Week 0.

參照圖7至圖10，相比飲用前（第0週），持續6週飲用山竹發酵飲料可使肌膚深層斑點顯著地減少約8.5%，使肌膚皺紋減少約8.3%，使肌膚紋理減少約6.7%，以及使肌膚含水量顯著地增加約18.6%。由此可知，長期使用山竹發酵液可改善肌膚狀況，即山竹發酵液具美肌之功效。Referring to Figure 7 to Figure 10, compared to before consumption (week 0), drinking mangosteen fermented beverage for 6 weeks can significantly reduce skin deep spots by about 8.5%, skin wrinkles by about 8.3%, and skin texture by about 6.7% %, and significantly increased skin moisture content by about 18.6%. It can be seen that long-term use of mangosteen fermented liquid can improve skin condition, that is, mangosteen fermented liquid has the effect of beautifying skin.

綜上所述，根據本發明任一實施例的山竹發酵液，其可製備美肌及/或減脂的組合物。換言之，前述之組合物具有下列一種或多種功能：提升抗氧化活性、抑制糖化終產物形成、抑制酪胺酸酶形成、抑制脂肪累積、減少受體的體脂肪以及改善肌膚狀況。To sum up, according to the mangosteen fermentation broth of any embodiment of the present invention, a composition for beautifying skin and/or reducing fat can be prepared. In other words, the aforementioned composition has one or more of the following functions: enhancing antioxidant activity, inhibiting glycation end product formation, inhibiting tyrosinase formation, inhibiting fat accumulation, reducing receptor body fat, and improving skin condition.

無without

圖1是繪示山竹發酵前與發酵後的總多酚含量的變化之長條圖。 圖2是繪示各組別的相對糖化終產物形成量之長條圖。 圖3是繪示各組別的相對黑色素含量之長條圖。 圖4是繪示各組別的相對脂肪累積量之長條圖。 圖5是繪示一示範例之山竹發酵液使用前與使用後的全身體脂率的變化之長條圖。 圖6是繪示一示範例之山竹發酵液使用前與使用後的腰圍的變化之長條圖。 圖7是繪示一示範例之山竹發酵液使用前與使用後的相對肌膚深層斑點的變化之長條圖。 圖8是一示範例之山竹發酵液使用前與使用後的相對肌膚皺紋的變化之長條圖。 圖9是一示範例之山竹發酵液使用前與使用後的相對肌膚紋理的變化之長條圖。 圖10是一示範例之山竹發酵液使用前與使用後的相對肌膚含水量的變化之長條圖。FIG. 1 is a bar graph showing changes in total polyphenol content of mangosteen before and after fermentation. Figure 2 is a bar graph showing the relative amounts of glycation end products formed for each group. Figure 3 is a bar graph showing the relative melanin content of each group. FIG. 4 is a bar graph showing the relative fat accumulation of each group. FIG. 5 is a bar graph showing the change of the whole body fat percentage before and after use of the mangosteen fermentation broth of an exemplary example. Fig. 6 is a bar graph showing the change of waist circumference before and after use of the mangosteen fermentation liquid of an example. FIG. 7 is a bar graph showing changes in relative skin deep spots before and after use of the mangosteen fermentation liquid of an exemplary example. Fig. 8 is a bar graph of changes in relative skin wrinkles before and after use of the mangosteen fermentation liquid of an exemplary example. Fig. 9 is a bar graph showing the change in relative skin texture of the mangosteen fermentation liquid before and after use. Fig. 10 is a bar graph showing changes in relative skin moisture content before and after use of the mangosteen fermentation broth of an exemplary example.

Claims (9)

一種山竹發酵液的用途，其是用於製備用以抑制糖化終產物形成的組合物，其中該山竹發酵液是由一山竹培養液依序與醋酸菌、乳酸菌及醋酸菌進行三段發酵程序所得，其中該山竹培養液包括山竹及水，該山竹與該水的比例為1：2-5，以及相對於該山竹培養液，該複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。 A kind of purposes of mangosteen fermentation liquid, it is used for preparing the composition in order to inhibit the formation of saccharification end product, wherein this mangosteen fermentation liquid is obtained by carrying out three stages of fermentation procedures with acetic acid bacteria, lactic acid bacteria and acetic acid bacteria in sequence by a mangosteen culture liquid , wherein the mangosteen culture solution comprises mangosteen and water, the ratio of the mangosteen to the water is 1:2-5, and relative to the mangosteen culture solution, the plurality of strains include 0.01%-0.5% yeast, 0.01%- 0.25% lactic acid bacteria and 1%-15% acetic acid bacteria. 一種山竹發酵液的用途，其是用於製備用以抑制酪胺酸酶形成的組合物，其中該山竹發酵液是由一山竹培養液依序與醋酸菌、乳酸菌及醋酸菌進行三段發酵程序所得，其中該山竹培養液包括山竹及水，該山竹與該水的比例為1：2-5，以及相對於該山竹培養液，該複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。 The purposes of a kind of mangosteen fermentation liquid, it is for preparing the composition in order to inhibit the formation of tyrosinase, wherein the mangosteen fermentation liquid is carried out by a mangosteen culture liquid sequentially with acetic acid bacteria, lactic acid bacteria and acetic acid bacteria to carry out three-stage fermentation procedures Gain, wherein this mangosteen culture solution comprises mangosteen and water, the ratio of this mangosteen and this water is 1:2-5, and with respect to this mangosteen culture solution, this plurality of bacterial classifications comprises 0.01%-0.5% yeast, 0.01% -0.25% lactic acid bacteria and 1%-15% acetic acid bacteria. 一種山竹發酵液的用途，其是用於製備用以抑制脂肪累積的組合物，其中該山竹發酵液是由一山竹培養液依序與醋酸菌、乳酸菌及醋酸菌進行三段發酵程序所得，其中該山竹培養液包括山竹及水，該山竹與該水的比例為1：2-5，以及相對於該山竹培養液，該複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。 A kind of purposes of mangosteen fermentation liquid, it is for preparing the composition in order to suppress fat accumulation, and wherein this mangosteen fermentation liquid is obtained by a mangosteen culture liquid and acetic acid bacteria, lactic acid bacteria and acetic acid bacteria to carry out three-stage fermentation procedures in sequence, wherein The mangosteen culture solution includes mangosteen and water, the ratio of the mangosteen to the water is 1:2-5, and relative to the mangosteen culture solution, the plurality of strains include 0.01%-0.5% yeast, 0.01%-0.25% Lactic acid bacteria and 1%-15% acetic acid bacteria. 一種山竹發酵液的用途，其是用於製備用以減少一受體的體脂肪的組合物，其中該山竹發酵液是由一山竹培養液依序與醋酸菌、乳酸菌及醋酸菌進行三段發酵程序所得，其中該山竹培養液包括山竹及水，該山竹與該水的比例為1：2-5，以及相對於該山竹培養液，該複數 菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。 A kind of purposes of mangosteen fermentation liquid, it is for preparing the composition in order to reduce the body fat of a receptor, wherein this mangosteen fermentation liquid is carried out three-stage fermentation with acetic acid bacteria, lactic acid bacteria and acetic acid bacteria sequentially by a mangosteen culture liquid Program obtained, wherein the mangosteen culture solution comprises mangosteen and water, the ratio of the mangosteen to the water is 1:2-5, and relative to the mangosteen culture solution, the plurality of The strains include 0.01%-0.5% yeast, 0.01%-0.25% lactic acid bacteria and 1%-15% acetic acid bacteria. 一種山竹發酵液的用途，其是用於製備用以改善肌膚狀況的組合物，其中該山竹發酵液是由一山竹培養液依序與醋酸菌、乳酸菌及醋酸菌進行三段發酵程序所得，其中該山竹培養液包括山竹及水，該山竹與該水的比例為1：2-5，以及相對於該山竹培養液，該複數菌種包括0.01%-0.5%的酵母菌、0.01%-0.25%的乳酸菌及1%-15%的醋酸菌。 A kind of purposes of mangosteen fermentation liquid, it is for preparing the composition in order to improve skin condition, wherein this mangosteen fermentation liquid is obtained by carrying out three-stage fermentation procedure with acetic acid bacteria, lactic acid bacteria and acetic acid bacteria sequentially by a mangosteen culture liquid, wherein The mangosteen culture solution includes mangosteen and water, the ratio of the mangosteen to the water is 1:2-5, and relative to the mangosteen culture solution, the plurality of strains include 0.01%-0.5% yeast, 0.01%-0.25% Lactic acid bacteria and 1%-15% acetic acid bacteria. 如請求項5所述的用途，其中改善該肌膚狀況為提升肌膚含水量、降低深層斑、減少皺紋、減少肌膚紋理或其組合。 The use of claim 5, wherein improving the skin condition is increasing skin moisture content, reducing deep spots, reducing wrinkles, reducing skin texture, or a combination thereof. 如請求項1至6中的任一項所述的用途，其中該發酵程序包括：添加該酵母菌至該山竹培養液內；將該山竹培養液與該酵母菌進行發酵1日至3日以形成一第一初發酵液，其中該酵母菌為Saccharomyces cerevisiae；添加該乳酸菌至該第一初發酵液內；將該第一初發酵液與該乳酸菌進行發酵1日至5日以形成一第二初發酵液，其中該乳酸菌為Lactobacillus plantarum；添加該醋酸菌至該第二初發酵液內；將該第二初發酵液與該醋酸菌進行發酵3日至10日以形成一第三初發酵液，其中該醋酸菌為Acetobacter aceti；以及過濾該第三初發酵液以得到該山竹發酵液。 The use according to any one of claims 1 to 6, wherein the fermentation procedure comprises: adding the yeast into the mangosteen culture solution; fermenting the mangosteen culture solution and the yeast for 1 to 3 days for forming a first initial fermentation liquid, wherein the yeast is Saccharomyces cerevisiae; adding the lactic acid bacteria to the first initial fermentation liquid; fermenting the first initial fermentation liquid and the lactic acid bacteria for 1 to 5 days to form a second Initial fermentation liquid, wherein the lactic acid bacteria is Lactobacillus plantarum; adding the acetic acid bacteria into the second initial fermentation liquid; fermenting the second initial fermentation liquid and the acetic acid bacteria for 3 to 10 days to form a third initial fermentation liquid , wherein the acetic acid bacteria is Acetobacter aceti; and filter the third primary fermentation broth to obtain the mangosteen fermentation broth. 如請求項7所述的用途，其中該山竹發酵液的pH值為3.7±1.0，且該山竹發酵液的糖度為40±2。 The use according to claim 7, wherein the pH value of the mangosteen fermentation broth is 3.7±1.0, and the sugar content of the mangosteen fermentation broth is 40±2. 如請求項1至6中的任一項所述的用途，其中該山竹發酵液的多酚含量為691ppm。The use according to any one of claims 1 to 6, wherein the polyphenol content of the mangosteen fermentation broth is 691 ppm.
TW109126981A 2019-08-27 2020-08-07 Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat TWI754345B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962892182P 2019-08-27 2019-08-27
US62/892,182 2019-08-27

Publications (2)

Publication Number Publication Date
TW202108160A TW202108160A (en) 2021-03-01
TWI754345B true TWI754345B (en) 2022-02-01

Family

ID=74733487

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109126981A TWI754345B (en) 2019-08-27 2020-08-07 Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat

Country Status (2)

Country Link
CN (1) CN112438922B (en)
TW (1) TWI754345B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013129334A1 (en) * 2012-02-28 2013-09-06 キッコーマン株式会社 AGONIST THAT MIMICS MOTIONAL EFFECT, AND CO-ACTIVATOR FOR AMPK AND PPARδ
CN103393576B (en) * 2013-08-07 2015-12-23 伽蓝（集团）股份有限公司 A kind of mangosteen extract and application thereof
KR102163969B1 (en) * 2017-03-20 2020-10-12 (주)지에프씨생명과학 Cosmetic Compositions Containing Fermented Extracts of Vernicia fordii
CN107648117A (en) * 2017-10-31 2018-02-02 广州赛莱拉干细胞科技股份有限公司 A kind of whitening spot-removing skin care item and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
于立梅等，山竹酒發酵過程中活性成分變化及成品香氣分析，現代食品科技2014;30(5):287-291;查勇，抗氧化菌的篩選及抗氧化發酵飲料的研究，江南大學碩士論文，2009/03 *
查勇，抗氧化菌的篩選及抗氧化發酵飲料的研究，江南大學碩士論文，2009/03。

Also Published As

Publication number Publication date
CN112438922A (en) 2021-03-05
TW202108160A (en) 2021-03-01
CN112438922B (en) 2023-04-07

Similar Documents

Publication Publication Date Title
TWI693899B (en) Fermentation product of punica granatum and uses thereof
TWI774046B (en) Use of solanum muricatum fermented liquid for preparing a composition for promoting skin anti-aging ability, promoting anti-glycation ability, reducing melanin content, increasing skin moisturization, reducing skin texture, reducing skin wrinkles, reducing skin redness and/or reducing fat
JP4942322B2 (en) Skin fibroblast proliferation promoter
JP6446120B2 (en) A composition for improving skin containing pomegranate concentrate as an active ingredient
TW201808324A (en) Skin external agent for skin whitening comprising an extract of fermented wheat germ
JPWO2018123828A1 (en) Fermented product and method for producing the same
TWI737086B (en) Fermentation method for increasing content of effective components in plants
TWI754345B (en) Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat
KR20210045529A (en) Method for preparing fermentated ziziphus jujuba seed
TWI747488B (en) Use of citrus medica var. sarcodactylis fermented liquid for preparing a composition for improving skin condition
TWI809308B (en) Use of wasabia japonica leaves for inhibiting the production of acne and reducing cutibacterium acnes secretions
WO2020226022A1 (en) External agent for hair restoration/hair growth
TWI779296B (en) Fermentation product of black rice extract and preparation and use of the same
TW201242607A (en) Whitening agent
KR101995384B1 (en) Composition for skin whitening and anti-oxidation comprising fermented Gynura procumbens as effective component
TWI774168B (en) Morus alba ferment, manufacturing method thereof and use thereof
CN113631227A (en) Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic
TWI830382B (en) Prunus salicina ferment, manufacturing method thereof, and uses thereof
TWI804771B (en) Uses of coffee cherry extract for inhibiting and/or reducing the production of collagen glycation end-products
TWI680772B (en) A use of lactobacillus plantarum gmnl-6 composition for caring skin
WO2024008187A1 (en) Use of prunus lannesiana extract in preparation of drug for improving skin condition or basal metabolic rate
TWI774055B (en) Buckwheat sprout extract, use thereof for preparing composition for enhancing cellular antioxidant and/or keeping liver health, and preparing method thereof
JP2021195341A (en) Skin external preparation
CN116426408A (en) Use of lactobacillus sake or its metabolites for the production of spermidine
TW202306582A (en) White asparagus ferment and use thereof for improving skin condition, promoting physiological metabolic activity and protecting kidney function